tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Aug 3;ciaa1143.
doi: 10.1093/cid/ciaa1143. Online ahead of print.
Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection
Kai Wang[SUP] 1 [/SUP], Quan-Xin Long[SUP] 1 [/SUP], Hai-Jun Deng[SUP] 1 [/SUP], Jie Hu[SUP] 1 [/SUP], Qing-Zhu Gao[SUP] 1 [/SUP], Gui-Ji Zhang[SUP] 1 [/SUP], Chang-Long He[SUP] 1 [/SUP], Lu-Yi Huang[SUP] 1 [/SUP], Jie-Li Hu[SUP] 1 [/SUP], Juan Chen[SUP] 1 [/SUP], Ni Tang[SUP] 1 [/SUP], Ai-Long Huang[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies (NAbs) in COVID-19 patients.
Methods: Blood samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines.
Results: SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symptom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset. NAb titers in 93?3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34?8% (IQR 19?6-42?4%). NAb titers increased over time in parallel with the rise in IgG antibody levels, correlating well at week 3 (r = 0?41, p & 0?05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including SCF, TRAIL, and M-CSF.
Conclusions: These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.
Keywords: COVID-19; SARS-CoV-2; longitudinal dynamics; neutralizing antibodies; serological immune response.
. 2020 Aug 3;ciaa1143.
doi: 10.1093/cid/ciaa1143. Online ahead of print.
Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection
Kai Wang[SUP] 1 [/SUP], Quan-Xin Long[SUP] 1 [/SUP], Hai-Jun Deng[SUP] 1 [/SUP], Jie Hu[SUP] 1 [/SUP], Qing-Zhu Gao[SUP] 1 [/SUP], Gui-Ji Zhang[SUP] 1 [/SUP], Chang-Long He[SUP] 1 [/SUP], Lu-Yi Huang[SUP] 1 [/SUP], Jie-Li Hu[SUP] 1 [/SUP], Juan Chen[SUP] 1 [/SUP], Ni Tang[SUP] 1 [/SUP], Ai-Long Huang[SUP] 1 [/SUP]
Affiliations
- PMID: 32745196
- DOI: 10.1093/cid/ciaa1143
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies (NAbs) in COVID-19 patients.
Methods: Blood samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines.
Results: SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symptom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset. NAb titers in 93?3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34?8% (IQR 19?6-42?4%). NAb titers increased over time in parallel with the rise in IgG antibody levels, correlating well at week 3 (r = 0?41, p & 0?05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including SCF, TRAIL, and M-CSF.
Conclusions: These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.
Keywords: COVID-19; SARS-CoV-2; longitudinal dynamics; neutralizing antibodies; serological immune response.